Previous 10 | Next 10 |
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) traded today at a new 52-week high of $8.41. So far today approximately 301,000 shares have been exchanged, as compared to an average 30-day volume of 1.3 million shares. Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) defies analysts with a curren...
Start Time: 08:30 End Time: 09:31 Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2021 Earnings Conference Call March 17, 2022, 08:30 AM ET Company Participants Patrick McEnany - Co-Founder, Chairman, President and CEO Alicia Grande - VP, CFO and Treasurer Steven Miller - COO and Chief Scientific Of...
Catalyst Pharmaceuticals (NASDAQ:CPRX) saw its Q4 2021 net income decline ~19% year over year even though revenue increased and beat estimates. Q4 net income stood at ~$9.3M ($0.09 per share, basic and diluted). Revenue increased ~24% year over year to ~$38.1M. Total operating costs and expen...
Catalyst Pharmaceuticals press release (NASDAQ:CPRX): Q4 GAAP EPS of $0.09 misses by $0.03. Revenue of $38.31M (+23.5% Y/Y) beats by $0.13M. Shares -0.13%. Strong 2022 Revenue Growth Expected, Supported by FIRDAPSE® Orphan Drug Exclusivity. New Patent Issuances Strengthens FIRDAPSE ...
Total 2021 Revenues Increased Approximately 18% YoY to $141 Million Strong 2022 Revenue Growth Expected, Supported by FIRDAPSE ® Orphan Drug Exclusivity New Patent Issuances Strengthens FIRDAPSE Long-Term Commercial Potential to 2034 Actively Pursuing Op...
IDEX, LEN, WSM, PD, CPRX, NBEV, SYN, OTCQX:MRMD, REI, OTCQX:TRSSF, ZTO, ASM, SMTC, GES, LGO, SMTS, BAK, LMB, LFT, EDR, ETON, IMV, PANL For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Wednesday's close
Catalyst Pharmaceuticals (NASDAQ:CPRX) is scheduled to announce Q4 earnings results on Wednesday, March 16th, after market close. The consensus EPS Estimate is $0.12 (+9.1% Y/Y) and the consensus Revenue Estimate is $38.18M (+23.1% Y/Y). Over the last 1 year, CPRX has beaten EPS estimates 100...
CORAL GABLES, Fla., March 11, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rar...
CORAL GABLES, Fla., March 08, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living wit...
CORAL GABLES, Fla., March 03, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living wit...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Pharmaceuticals Inc. Company Name:
CPRX Stock Symbol:
NASDAQ Market:
Catalyst Pharmaceuticals Inc. Website:
CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-...
CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-...
2024-06-20 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...